Robert Orlowski, Deputy Chair of Lymphoma/Myeloma, Vice Chair of MM Research, and Florence Maude Thomas Cancer Research Professor at the University of Texas MD Anderson Cancer Center, shared a post on X:
“Myeloma Paper of the Day: GEM12 phase III trial of BUMEL (n=230) vs. MEL200 (n=228) conditioning with ASCT after induction with 6 VRD cycles followed by two VRD consolidation cycles finds median PFS 89 vs. 73.1 months in the two arms; HR 0.89, P= 0.3.”
Title: High-dose busulfan-melphalan vs melphalan and reinforced VRD for newly diagnosed multiple myeloma: a phase 3 GEM trial
Authors: Juan-Jose Lahuerta, Jesús F. San-Miguel, Ana Jiménez-Ubieto, Rafael Alonso Fernández, Bruno Paiva, Noemi Puig, Maria-Teresa Cedena, Norma C Gutierrez, Maria José Calasanz, Manuela Fernandez, Rafael Ríos-Tamayo, Albert Oriol, María-Jesús Blanchard, Estrella Carrillo-Cruz, Rafael Martínez-Martínez, Joan Bargay, Anna Sureda, Javier de la Rubia, Miguel-Teodoro T. Hernandez Garcia, Valentín Cabañas, Luis Felipe Casado Montero, Luis Palomera Bernal, Yolanda Gonzalez-Montes, Joaquín Martínez-López, Paula Rodriguez-Otero, Isabel Krsnik, Jose M Arguiñano, María Esther Gonzalez-Garcia, Enrique M. Ocio, Javier de la Cruz, Maria-Victoria Mateos, Laura Rosiñol, Joan Bladé.
You can read the Full Article in Blood.
More posts featuring Robert Orlowski.
